Fin Cascade

Prices as of 20 Nov 2026 close · Not investment advice

Updated 21 Nov, 21:20 IST

Shukra Medtech Limited

NSE: SHUKRAMED · Pharmaceuticals

Share price ₹84.16

close of 20 Nov 2026

Business scoreHow strong the business is, in one number.Changed 20 Nov 2026How it was built →

Your ratios

Market cap

₹3,725 Cr

P/E ratio

84.1

EPS TTM to Sep 2026

P/B ratio

31.6

ROCE

37.0%

ROE

28.8%

Dividend yield

0.0%

as of 20 Nov 2026

Profit checks6/7 clear

1 · Overview

Overview

Price, valuation, sales and profit over the range you pick. Prices as of the last close; results as filed.

Price
Loading SHUKRAMED data…

At a glance · Max

Every small chart follows the range above. Point at it to read a value; click it to open it.
Revenue (sales)
₹44.0 Cr
Sep 2026 · +633.33% on a year ago
Sep 2023 – Sep 2026 · 13 quarters
Operating margin
42.0%
average 35.5% · low −7.0% · high 81.0%
Sep 2023 – Sep 2026 · 13 quarters
Net profit
₹13.0 Cr
Sep 2026 · +550.00% on a year ago
Sep 2023 – Sep 2026 · 13 quarters
EPS (yearly)
₹0.50
FY26 · +127.27% on FY25
FY15 – FY26 · 12 years
ROCE (yearly)
44%
FY24 · average 9% over 10 years
FY15 – FY24 · 10 years
Promoter holding
51.16%
FII 0.4% · DII 0.2% · +0.21 pts in a year
Dec 2023 – Sep 2026 · 12 quarters

2 · Results

Latest result · Q2 FY27

What the last results showed. Whether management kept its word is in Pro.

Net profit ₹13.0 Cr, up 550.0% on Sep 2025

Quarter to Sep 2026 · Consolidated · next results expected soon

Sales₹44.0 Crup 633.3% on Sep 2025
Operating profit₹19.0 Crno comparison with Sep 2025
Operating margin42.0%up 49.0 pts from -7.0%
Net profit₹13.0 Crup 550.0% on Sep 2025
Net margin29.5%down 3.8 pts from 33.3%
EPS₹0.29up 480.0% on Sep 2025
Sales, last 8 quarters ₹ crore
Show
Consolidated
Sales, operating profit and net profit, ₹ crore: 12 years to Mar 2026, then the last 12 months (the fainter bars).
TTMLast 12 months to Sep 2026
Sales₹113 Cr
Operating profit₹66 Cr58.4% of sales
Net profit₹44 Cr38.9% of sales
P/E84.1On 20 Nov 2026
Inside each sales bar: operating profit, and inside that, net profit.OPM: operating profit as % of sales. NPM: net profit as % of sales.P/E on the last trading day of each period: that day's share price ÷ the 12-month earnings per share published by then. Blank where none is on record.

Years to March, 2015–2026, and the last 12 months · key lines

Yearly profit and loss, Years to March, 2015–2026, and the last 12 months
LineMar 2015FY15Mar 2016FY16Mar 2017FY17Mar 2018FY18Mar 2019FY19Mar 2020FY20Mar 2021FY21Mar 2022FY22Mar 2023FY23Mar 2024FY24Mar 2025FY25Mar 2026FY26TTMto Sep 2026
Sales₹ crore35change on a year before +67%5change on a year before 0%5change on a year before 0%6change on a year before +20%12change on a year before +100%11change on a year before -8%20change on a year before +82%59change on a year before +195%75change on a year before +27%33change on a year before -56%57change on a year before +73%113change on a year before +223%
Operating profit₹ crore011change on a year before 0%2change on a year before +100%2change on a year before 0%2change on a year before 0%1change on a year before -50%3change on a year before +200%5change on a year before +67%19change on a year before +280%13change on a year before -32%29change on a year before +123%66change on a year before +450%
Operating margin% of sales-10.00%24.00%28.00%30.00%29.00%13.00%13.00%14.00%9.00%26.00%39.00%51.00%58.41%
Other income₹ crore1000000013454
Net profit₹ crore00010change on a year before -100%0014change on a year before +300%19change on a year before +375%10change on a year before -47%22change on a year before +120%44change on a year before +300%
EPS₹ per share0.000.000.020.02change on a year before 0%0.02change on a year before 0%0.00change on a year before -100%0.010.02change on a year before +100%0.15change on a year before +650%0.42change on a year before +180%0.22change on a year before -48%0.50change on a year before +127%1.00change on a year before +285%
Dividend paid out% of net profit0.00%0.00%16.00%15.00%17.00%0.00%0.00%10.00%4.00%6.00%5.00%2.00%

Small figure: change on the year before (TTM: on the 12 months to Sep 2025). TTM = the four quarters to Sep 2026.

Filed only on the standalone basis, so shown from it: Depreciation, Dividend paid out, EPS, Expenses, Interest, Net profit, Operating margin, Operating profit, Other income, Profit before tax, Sales, Sales growth, Tax rate.

Sales and profit: growth a year, compounded, to Mar 2026; TTM is the last 12 months. Share price: to the latest close. A span can cross a demerger or an acquisition.

Sales

a year, compounded

3 years
-1%
TTM
222%

3 years: base year from the standalone accounts; the consolidated accounts start later.

Profit

a year, compounded

TTM
300%

Share price

a year, compounded

10 years
70%
5 years
212%
3 years
231%
1 year
97%

Return on equity

average over the span

Last year
29%

3 · Quality & value

Answers

The questions investors ask most, each answered first in one line, then shown. From the company's own numbers.

How fast it has been growing

Our sales figures for this company step up at Jun 2026 and we hold nothing that says why, so we cannot honestly quote a growth rate across it.

Whether it grew faster than its sector

We do not have three full years of its sales yet, so there is nothing to compare with its sector.

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

It has no steady three-year profit record yet, so growth cannot be weighed against the price.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 10 of 132 on returns, 3 of 132 on margin.

Returns on capital10 of 132
Margin3 of 132

A longer bar is a better rank.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 37.0% on capital, ahead of 92% of companies filed under the same label.

Return on capital37.0%
Ahead of92% of peers

Whether its growth pays for itself

Only 2 years of matching accounts on file — too few to judge this yet.

Peers here are the 132 companies the exchange files under the same label (Pharmaceuticals). That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Business score & profit checks

How strong the business is, and whether its profit is real cash. Facts only, not advice.

Business score

59 out of 100

How strong the business is, in one number. Last changed 20 Nov 2026.

How the business score works

Profit checks: is the profit real cash?

6 of 7 checks clear

2 of 9 checks could not be run.

Simple checks on the accounts. Which one is flagged is in Pro.

How the profit check works

PROHow the score was builtEach part of the score, with the numbers behind it
PROWhich checks were flaggedEvery check, the watch list and the filings behind them
PROFrom the filingsLoan defaults, and money lent or guaranteed to the promoters’ side
PROThe case for and againstA weighted list of what looks good and what looks weak

Key numbers & peers

Grouped by topic. Each number says what period it is for.

Price

Market cap
₹3,725 Cr
Prev close
₹84.16
52w High
—
52w Low
—
Beta
—
Price CAGR 1y
97.0%
Price CAGR 3y
231.0%
Price CAGR 5y
212.0%
Price CAGR 10y
70.0%

Valuation

P/E ratioEPS TTM to Sep 2026
84.1
Industry P/E
34.7
P/B ratio
31.6
EV / EBITDA
56.4
Enterprise value
₹3,724 Cr
PEG ratio
—
Dividend yield
0.0%

Returns

ROCE
37.0%
ROCE 5y average
26.5%
ROE
28.8%
ROE 3y average
—
ROE last year
29.0%
Return on assets
18.8%

Sales, profit & margins

Annual revenue
₹57.0 Cr
Annual profit
₹22.0 Cr
EPS
₹0.5
Operating margin
51.0%
Net profit margin
38.6%
EBITDA margin
50.9%
Sales latest quarterSep 2026 quarter
₹44.0 Cr
Profit latest quarterSep 2026 quarter
₹13.0 Cr
OPM latest quarterSep 2026 quarter
42.0%

Growth a year

Sales growth 3y
-1.1%
Sales growth 5y
—
Sales growth TTM
222.0%
Profit growth 3y
—
Profit growth 5y
—
Profit growth TTM
300.0%
YoY quarterly sales growthSep 2026 vs Sep 2025
633.3%
YoY quarterly profit growthSep 2026 vs Sep 2025
550.0%

Balance sheet

Book Value
₹2.7
Face Value
₹1.0
Borrowings
₹5.00 Cr
Total debt
₹22.0 Cr
Total cash
₹11.0 Cr
Net cashas of 31 Mar 2026
₹1.00 Cr
Debt / Equity
0.2
Interest coverage
30.0
Reserves / Equity
1.0

Cash & payout

Operating cash flow
₹3.00 Cr
Free cash flow
-₹13.0 Cr
FCF yield
-0.4%
Net cash flow
-₹6.00 Cr
Dividend payout
2.0%

Holdings

Promoter holding
51.2%
FII holding
0.4%
DII holding
0.2%
Public holding
48.2%

Enterprise value, step by step

What buying the whole company would cost: its market value, less the cash it holds over its debt. Net cash from the balance sheet of 31 Mar 2026.

  1. Market cap₹3,725 Cr
  2. −Net cash₹1.00 Cr
  3. =Enterprise value₹3,724 Cr

4 · Balance sheet & cash

Balance sheet

What the company owns and what it owes, at each year end and at the filed half-years. ₹ crore.

Consolidated

At Mar 2026: ₹117 cr of assets, and who funds them

Shareholders’ own money funds 77% of it; borrowings 4%.

What it owns

  • Fixed assets ₹22.0 cr 19%
  • Being built ₹12.0 cr 10%
  • Everything else ₹83.0 cr 71%

Who funds it

  • Shareholders’ money ₹90.0 cr 77%
  • Borrowings ₹5.00 cr 4%
  • Everything else ₹22.0 cr 19%

Each year end. Newest year end shaded.

Balance sheet
Line, ₹ croreMar 2025FY25Mar 2026FY26
Equity capital4444
Reserves1946
Borrowings45
Other liabilities2023
Total funding87117
Fixed assets1922
Being built (CWIP)212
Other assetsreceivables, cash, rest6584
Total assets87117

Cash flows

Real money coming in and going out — from the business, from investments and from loans. ₹ crore.

Consolidated

Pick a period to see where its cash went.

Where the cash went, year to Mar 2026, ₹ crore

In words

  • The business brought in ₹3.00 cr, 10% of its operating profit before tax.
  • It put ₹14.0 cr into assets and investments.
  • It raised ₹5.00 cr from shareholders and lenders.
  • Cash in hand fell by ₹6.00 cr. Free cash flow: −₹13.0 cr.
Cash flow
Line, ₹ croreMar 2025FY25Mar 2026FY26
From the business83
From investing-1-14
From financingdividends, buybacks, loans-55
Net change in cash2-6
Free cash flow5-13
Cash ÷ operating profitbefore tax62.00%10.00%

Free cash flow = cash from the business − spending on assets + what assets sold fetched; the same rule for years and half-years.

Efficiency ratios

How fast customers pay and how well capital earns. Each year, Mar 2015 to Mar 2026.

Consolidated

Debtor days

147 days

Days customers take to pay. Lower is faster.

147 days in FY26, against 100 days in FY25. Over these 12 years: 71 days (FY16) to 345 days (FY19).

Inventory days

320 days

Days stock sits before it is sold.

320 days in FY26, against 447 days in FY25. Over these 12 years: 19 days (FY24) to 554 days (FY15).

Days payable

232 days

Days it takes to pay its suppliers.

232 days in FY26, against 414 days in FY25. Over these 12 years: 59 days (FY24) to 1161 days (FY19).

Cash conversion cycle

236 days

Debtor days plus inventory days, less days payable.

236 days in FY26, against 131 days in FY25. Over these 12 years: −717 days (FY19) to 335 days (FY15).

Working capital days

352 days

Days of sales tied up in running the business.

352 days in FY26, against 403 days in FY25. Over these 12 years: 41 days (FY23) to 758 days (FY15).

Return on capital (ROCE)

37%

Operating profit on the capital used.

37% in FY26. Over these 11 years: −1% (FY15) to 44% (FY24).

Filed only on the standalone basis, so shown from it: Cash Conversion Cycle, Days Payable, Debtor Days, Inventory Days, ROCE %, Working Capital Days.

5 · Owners & payouts

Shareholding pattern

Who owns the company: promoters, foreign funds, Indian funds and the public, at each quarter end. In %.

To 30 Sep 2026

Share of the company held by each group, at each filed quarter end, Dec 2023 to Sep 2026.

Promoters

The group that controls the company

51.16%

Since Dec 2023 +0.21 pts

Foreign funds (FIIs)

Investors outside India

0.43%

Since Dec 2023 +0.43 pts

Indian funds (DIIs)

Mutual funds, insurers, banks

0.21%

Since Dec 2023 +0.10 pts

Public

Individuals and others

48.20%

Since Dec 2023 −0.73 pts

Number of shareholders

Accounts holding the share

35,007

Since Dec 2023 +24,044

  • Foreign funds raised their share from 0.00% to 0.43%; Indian funds raised theirs from 0.11% to 0.21%.
  • Promoters held 51.16% at Sep 2026, against 50.95% at Dec 2023.
  • Shareholders grew from 10,963 to 35,007.
Shareholding, % of the company at each quarter end
Holder, %Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoters50.9550.9550.9550.9550.9550.9550.9550.9550.9550.9550.9551.16+0.21
Foreign funds (FIIs)0.000.000.000.000.000.000.000.000.000.000.000.43+0.43
Indian funds (DIIs)0.110.110.110.110.110.110.110.110.110.110.110.21+0.10
Public48.9348.9348.9348.9348.9348.9348.9348.9348.9348.9248.9348.20−0.73
Shareholders10,96312,97414,98916,32117,84418,23120,33721,44125,64927,17328,38435,007+24,044

A figure in bold moved by 0.5 points or more from the quarter before. Change = Sep 2026 against Dec 2023, in points.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividend a share, by the year of its ex-date

No dividend on record.

Share of profit paid as dividend

Each year, Mar 2015 to Mar 2026.

Splits, bonuses & buybacks

None on record.

Big trades by funds and insiders

None listed for this company.

6 · Price & trading

Open interestPRO

Where option traders are positioned on this stock.

7 · Business

About

What the company is, from our own records: where it sits, where its revenue comes from, and where it works.

Sector
Healthcare
Industry
Pharmaceuticals
Symbol
SHUKRAMED
ISIN
INE551C01044

Industry numbers

The numbers that matter most in this industry, from the company's own filings and earnings calls. Each one says its period.

Revenue and margin

  • EBIT marginSep 2026 quarter40.91%

Working capital

  • Days sales outstanding12 months to Sep 2026126 days

Profit quality

  • Other income shareSep 2026 quarter5.56%

Returns

  • RoE12 months to Mar 202627.45%
  • RoA12 months to Mar 202620.59%
  • Sales to net block12 months to Sep 20265.38x

Leverage

  • Net debt to EBITDA12 months to Mar 2026-0.03x

Growth

  • Revenue growth (YoY)Sep 2026 quarter633.33%

Capex

  • CapexFY to Mar 2026₹16.0 Cr
  • Capex to revenueFY to Mar 202628.07%

How they have moved

EBIT margin · quarterly

Source: Computed from the filings

Sep 2640.91%Computed from the filings
Jun 26—not filed
Mar 260.00%Computed from the filings
Dec 25—not filed

Other income share · quarterly

Source: Computed from the filings

Sep 265.56%Computed from the filings
Jun 265.56%Computed from the filings
Mar 26—not filed
Dec 253.70%Computed from the filings

Revenue growth (YoY) · quarterly

Source: Computed from the filings

Sep 26633.33%Computed from the filings
Jun 26380.00%Computed from the filings
Mar 26-53.85%Computed from the filings
Dec 25254.55%Computed from the filings

Capex (fiscal year) · yearly

Source: Computed from the filings

FY26₹16.0 CrComputed from the filings
FY25₹3.00 CrComputed from the filings

Capex to revenue (fiscal year) · yearly

Source: Computed from the filings

FY2628.07%Computed from the filings
FY259.09%Computed from the filings

Supply chain

Links to other companies, as recorded in our map from filings and announcements. A news event that hits one of them can reach Shukra Medtech Limited through this map.

No supply-chain links recorded for this company yet.

8 · News & documents

News and what it reaches

Filings and news about Shukra Medtech Limited, and bigger events that reach it through its owners, rivals, customers or suppliers. Newest first. Open one to see how the effect spreads.

No recent news or filings for this company.

Documents

Earnings calls, results presentations and annual reports, straight from the company and the exchanges.

No documents on record yet.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.